May 2022

American Cancer Society’s Impact Venture Capital Fund Releases Performance Results to Date

ATLANTA, May 19, 2022 -- The American Cancer Society’s impact venture capital fund, BrightEdge LLC, today reported $9.7 million in realized and unrealized investment gains on $18.5 million in invested capital through year-end 2021. BrightEdge’s net asset value now stands at roughly $77 million, including recent donations and an additional $40 million investment from the American Cancer Society (ACS).

Click the link to read full report